Dewpoint partners its ALS program, eyes JPM to raise a Series D

Molecular condensates startup Dewpoint Therapeutics has signed on its latest partner, this time forging a future for its ALS program with Mitsubishi Tanabe Pharma Corporation in a pact worth up to $480 million. Dewpoint CEO ...